摘要
目的观察顺尔宁联用普米克令舒＋博利康尼氧驱动雾化吸入治疗小儿支气管哮喘的疗效。方法对收住的25例支气管哮喘并肺部感染患儿的临床资料进行回顾性分析。结果顺尔宁联用普米克令舒＋博利康尼雾化吸入治疗小儿支气管哮喘并肺部感染的半年复发率为0，单纯用普米克令舒＋博利康尼氧驱动雾化吸入治疗小儿支气管哮喘并肺部感染的半年复发率为46．7％。结论顺尔宁联用普米克令舒＋博利康尼氧驱动雾化吸人治疗小儿支气管哮喘并肺部感染疗效显著，值得临床推广应用。
Objective To observe the therapeutic effects of montelukast sodium chewable tablets and budesonide suspension for inhalation plus terbutaline sulphate solution for nebulisation in bronchial asthmatic children. Method Proceed with the review analysis of 25 examples of bronchial asthmatic children, llesult Bronchial asthmatic children with the treatment of montelukast sodium chewable tablets and budesonide suspension for inhalation plus terbutaline sulphate solution for nebulisation, whose halfyearly setback rate is 0.Conclusions Those without montelukast sodium chewable tablets whose halfyearly setback rate is 46.7%.
出处
《国际医药卫生导报》
2010年第9期1085-1087,共3页
International Medicine and Health Guidance News
关键词
顺尔宁
雾化吸入
小儿支气管哮喘并肺部感染
Montelukast sodium chewable tablets
Budesonide suspension for inhalation
Terhutaline sulphate solution for nebulisation
